4 active not recruiting, 2 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 4, Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Poseida Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate - Multiple Myeloma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 275 | 2022-05-05 | 2026-04-24 |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors P-MUC1C-ALLO1 CAR-T cells, Rimiducid - Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 180 | 2022-02-15 | 2026-11-05 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) P-PSMA-101 CAR-T cells, Rimiducid - Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type | Phase 1 | Terminated | Poseida Therapeutics, Inc. | 40 | 2020-02-28 | 2025-02-17 |
| Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Rimiducid may be administered as indicated - Multiple Myeloma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 100 | 2018-10-29 | 2026-03-04 |
| P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) P-BCMA-101 CAR-T cells, Rimiducid - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Poseida Therapeutics, Inc. | 105 | 2017-09-20 | 2024-03-28 |
Multiple Myeloma (3) · Breast Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Genital Neoplasms, Male (1) · Lymphoma, Large B-Cell, Diffuse (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1)
Methotrexate (1)
United States (6)
Rajesh Belani, M.D. (2) · Maika Onishi, M.D. (1) · Maika Onishi,, M.D., P.h.D (1) · Simon Heidegger, M.D. (1) · Simon Heidegger, MD (1)